REGENXBIO RGNX 深 沪
等待开盘 08-21 09:30:00 美东时间
8.07
+0.040
+0.50%
华盛通- 最 高8.19
- 今 开8.00
- 成交量 56.40万股
- 最 低 7.8298
- 昨 收 8.03
- 总市值 4.07亿
- 52周最高 13.48
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 5.035
- 委 比 -80.82%
- 总股本 5038.87万
- 历史最高 85.10
- 量 比 0.72
- 振 幅 4.49%
- 历史最低 5.035
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analyst Expectations For Regenxbio's Future
Across the recent three months, 5 analysts have shared their insights on Regenx...
08-19 20:00
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Pharmaceutical Inc. announced the initiation of a rolling submission of a Biologics License Application (BLA) to the FDA for DTX401 AAV gene therapy, intended to treat Glycogen Storage Disease Type Ia (GSDIa). The company has already submitted non-clinical and clinical modules and plans to complete the full BLA, including the chemistry, manufacturing, and controls (CMC) module, by the fourth quarter of 2025. The BLA includes 96-week da...
08-18 12:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.
08-08 20:10
RegenXBio and AbbVie Amend Collaboration Agreement
RegenXBio ( ($RGNX) ) has shared an update. On August 5, 2025, REGENXBIO Inc. a...
08-07 19:54
Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.10) by 25.8 percent. This is a 31.43 percent decrease over losses of $(1.05) per share from the
08-07 19:06
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
ProKidney Corp.'s Phase 2 REGEN-007 trial for rilparencel in CKD patients with diabetes shows statistically significant improvement in kidney function. Group 1 saw a 78% reduction in eGFR slope decline after two injections, while Group 2 showed a 50% improvement with an exploratory dosing regimen. No serious adverse events were reported. Results will be presented at the American Society of Nephrology 2025 Kidney Week. The FDA Type B meeting in su...
07-08 11:00
REGENXBIO registers 268K shares for resale
REGENXBIO (NASDAQ:RGNX) is registering up to 268,096 shares of common stock for resale by a selling stockholder. Shares are issuable upon exercise of a warrant priced at $14.92, issued in connection w...
06-14 05:34
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.
06-05 23:43
